Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical Affairs, Janssen Biolo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fitzgerald T, Melsheimer R, Lafeuille MH, Lefebvre P, Morrison L, Woodruff K, Lin I, Emond B
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	biosimilars chronic inflammatory disease treatment discontinuation infliximab treatment switching Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fad32ee9734e4ce0b8c50a317d79e827
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fad32ee9734e4ce0b8c50a317d79e827
record_format	dspace
spelling	oai:doaj.org-article:fad32ee9734e4ce0b8c50a317d79e8272021-12-02T15:07:16ZSwitching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab1177-5491https://doaj.org/article/fad32ee9734e4ce0b8c50a317d79e8272021-01-01T00:00:00Zhttps://www.dovepress.com/switching-and-discontinuation-patterns-among-patients-stable-on-origin-peer-reviewed-article-BTThttps://doaj.org/toc/1177-5491Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 3Analysis Group, Inc., Montréal, Québec, CanadaCorrespondence: Bruno EmondAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montreal, Tour Deloitte, Suite 1500, Montréal, QC H3B 0G7, CanadaTel +1 514-394-4455Fax +1 514-394-4461Email Bruno.Emond@analysisgroup.comObjective: To compare switching and discontinuation patterns of patients stable on originator infliximab (IFX) who switched to an IFX biosimilar (switchers) or remained on originator IFX (continuers) in the United States.Methods: Symphony Health Solutions’ Patient Transactional Datasets (10/2012– 03/2019) were used to identify adults with ≥ 2 claims for either rheumatoid arthritis (RA), psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, or inflammatory bowel disease (IBD); and ≥ 1 claim for originator or biosimilar IFX. The index date was the first IFX biosimilar claim for switchers or a random originator IFX claim for continuers. All patients were required to have ≥ 5 originator IFX claims during the 12 months pre-index (prevalent population). The subset of patients with ≥ 12 months of observation prior to the first originator IFX claim was also analyzed (incident population). Switchers were matched 1:3 to continuers. Discontinuation was defined as having ≥ 120 days between 2 consecutive index treatment claims.Results: Prevalent switchers (N=1109) were 3.57-times more likely than continuers (N=3327) to switch to another originator biologic (hazard ratio [HR]=3.57, p< 0.001). Of 249 prevalent switchers who switched to another originator biologic, 200 (80.3%) switched back to originator IFX. Incident switchers (N=571) were 2.55-times more likely than continuers (N=1713) to switch to another originator biologic (HR=2.55, p< 0.001). Of 118 incident switchers who switched to another originator biologic, 90 (76.3%) switched back to originator IFX. Prevalent switchers were 1.25-times more likely than continuers to discontinue index therapy (HR=1.25, p< 0.001). Similar results were observed in RA (prevalent population; switching: HR=3.49, p< 0.001; discontinuation: HR=1.23, p=0.009) and IBD (prevalent population; switching: HR=3.82, p< 0.001; discontinuation: HR=1.29, p=0.003) subgroups.Conclusion: Patients switching from originator to biosimilar IFX were more likely to switch to another originator biologic (notably back to originator IFX) and discontinue index treatment than those remaining on originator IFX; however, reasons for switching are unknown.Keywords: biosimilars, chronic inflammatory disease, treatment discontinuation, infliximab, treatment switchingFitzgerald TMelsheimer RLafeuille MHLefebvre PMorrison LWoodruff KLin IEmond BDove Medical Pressarticlebiosimilarschronic inflammatory diseasetreatment discontinuationinfliximabtreatment switchingMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol Volume 15, Pp 1-15 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	biosimilars chronic inflammatory disease treatment discontinuation infliximab treatment switching Medicine (General) R5-920
spellingShingle	biosimilars chronic inflammatory disease treatment discontinuation infliximab treatment switching Medicine (General) R5-920 Fitzgerald T Melsheimer R Lafeuille MH Lefebvre P Morrison L Woodruff K Lin I Emond B Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
description	Timothy Fitzgerald,1 Richard Melsheimer,2 Marie-Hélène Lafeuille,3 Patrick Lefebvre,3 Laura Morrison,3 Kimberly Woodruff,1 Iris Lin,1 Bruno Emond3 1Real World Value & Evidence, Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA; 2Medical Affairs, Janssen Biologics BV, Leiden, the Netherlands; 3Analysis Group, Inc., Montréal, Québec, CanadaCorrespondence: Bruno EmondAnalysis Group, Inc., 1190 Avenue des Canadiens-de-Montreal, Tour Deloitte, Suite 1500, Montréal, QC H3B 0G7, CanadaTel +1 514-394-4455Fax +1 514-394-4461Email Bruno.Emond@analysisgroup.comObjective: To compare switching and discontinuation patterns of patients stable on originator infliximab (IFX) who switched to an IFX biosimilar (switchers) or remained on originator IFX (continuers) in the United States.Methods: Symphony Health Solutions’ Patient Transactional Datasets (10/2012– 03/2019) were used to identify adults with ≥ 2 claims for either rheumatoid arthritis (RA), psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, or inflammatory bowel disease (IBD); and ≥ 1 claim for originator or biosimilar IFX. The index date was the first IFX biosimilar claim for switchers or a random originator IFX claim for continuers. All patients were required to have ≥ 5 originator IFX claims during the 12 months pre-index (prevalent population). The subset of patients with ≥ 12 months of observation prior to the first originator IFX claim was also analyzed (incident population). Switchers were matched 1:3 to continuers. Discontinuation was defined as having ≥ 120 days between 2 consecutive index treatment claims.Results: Prevalent switchers (N=1109) were 3.57-times more likely than continuers (N=3327) to switch to another originator biologic (hazard ratio [HR]=3.57, p< 0.001). Of 249 prevalent switchers who switched to another originator biologic, 200 (80.3%) switched back to originator IFX. Incident switchers (N=571) were 2.55-times more likely than continuers (N=1713) to switch to another originator biologic (HR=2.55, p< 0.001). Of 118 incident switchers who switched to another originator biologic, 90 (76.3%) switched back to originator IFX. Prevalent switchers were 1.25-times more likely than continuers to discontinue index therapy (HR=1.25, p< 0.001). Similar results were observed in RA (prevalent population; switching: HR=3.49, p< 0.001; discontinuation: HR=1.23, p=0.009) and IBD (prevalent population; switching: HR=3.82, p< 0.001; discontinuation: HR=1.29, p=0.003) subgroups.Conclusion: Patients switching from originator to biosimilar IFX were more likely to switch to another originator biologic (notably back to originator IFX) and discontinue index treatment than those remaining on originator IFX; however, reasons for switching are unknown.Keywords: biosimilars, chronic inflammatory disease, treatment discontinuation, infliximab, treatment switching
format	article
author	Fitzgerald T Melsheimer R Lafeuille MH Lefebvre P Morrison L Woodruff K Lin I Emond B
author_facet	Fitzgerald T Melsheimer R Lafeuille MH Lefebvre P Morrison L Woodruff K Lin I Emond B
author_sort	Fitzgerald T
title	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
title_short	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
title_full	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
title_fullStr	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
title_full_unstemmed	Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab
title_sort	switching and discontinuation patterns among patients stable on originator infliximab who switched to an infliximab biosimilar or remained on originator infliximab
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/fad32ee9734e4ce0b8c50a317d79e827
work_keys_str_mv	AT fitzgeraldt switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT melsheimerr switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT lafeuillemh switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT lefebvrep switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT morrisonl switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT woodruffk switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT lini switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab AT emondb switchinganddiscontinuationpatternsamongpatientsstableonoriginatorinfliximabwhoswitchedtoaninfliximabbiosimilarorremainedonoriginatorinfliximab
_version_	1718388490869145600

Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab

Ejemplares similares